Etikett: Nanexa

NANEXA: Variable roadmap with emphasis on NEX-22 and potential Novo Nordisk deal

Analys, Research

With the recently completed Phase 1 study for NEX-20 yielding positive results, and the widespread global interest in GLP-1, Nanexa now has...

Read More

NANEXA: Capital raise to pursue a broad set of opportunities in 2024 and 2025

Analys, Research

As we had expected, Nanexa announced a SEK 121m rights issue, albeit at a slightly higher than expected both discount and amount. This will...

Read More

NANEXA: Progress with NEX-20 and NEX-22 Amid Rising GLP-1 Interest

Analys, Research

Nanexa’s Q2’23 advancements with NEX-20 and NEX-22 underscore the company’s forward momentum. NEX-20 is set to provide a more...

Read More

NANEXA: Solid progress in development into 2023, with funding needs on the horizon

Analys, Research

After positive pre-clinical results in rats with NEX-22 (for treatment of type 2 diabetes) in Q1, we now see results from phase I for...

Read More

NANEXA: Validation from Novo Nordisk positions Nanexa for an eventful year ahead

Analys, Research

After a news packed Q4 2022, including an exclusivity and evaluation agreement with Novo Nordisk, start of Phase I with NEX-20 and two...

Read More

NANEXA: Novo Nordisk deal offers both scientific validation and investor-friendly financing

Analys, Research

The combination of an exclusive evaluation agreement and directed share issue to Novo Nordisk, global leader in diabetes treatment,...

Read More

NANEXA: Charging to enter triple clinical trials in the coming year

Analys, Research

Besides starting its third proprietary development project in Q2 (NEX-22, a long-acting formulation of liraglutide for treatment of type 2...

Read More

NANEXA: New project NEX-22 to add significant daily benefits for 50m patient market

Analys, Research

Nanexa’s next proprietary development project, NEX-22, is a long-acting formulation of liraglutide for treatment of type 2 diabetes...

Read More

NANEXA: New facility important step in scaling up activity with eventful year ahead

Analys, Research

Johan Widmark | 2022-06-13 08:00  READ FULL REPORT HERE IN PDF New facility up and running While the inauguration of Nanexa’s new...

Read More

Start av Nanexas produktionsanläggning och klinisk studie av NEX-20 fokus 2022

Analys

Med en plan framåt för NEX-18 och nya produktionsanläggningen snart i drift ser vi ljust på chanserna för ett avtal om...

Read More

For new research on growth stocks, sign up to our newsletter